Article
A prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved to be effective and without potentially allergic lung reactions.
All News
Article
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.
Article
The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) for the treatment of gout flares in adults who cannot be treated with NSAIDs, colchicine, or repeated courses of corticosteroids. The drug is also indicated for people who could not tolerate or had an inadequate response to NSAIDs or colchicine.
Article
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.
Article
A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance and expert opinion on the evaluation, management and monitoring of patients with Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with the primary intent to halt disease progression and prevent life-threatening complications from HLH/MAS.
Robert B Chao, MD
Tweet
Is there a difference in secukinumab vs. adalimumab biosimilar on radiographic progression in a subgroup of axSpA pts with syndesmophytes or CRP levels?
Radiographic progression equally low in both drugs
NO difference in syndesmophytes or CRP
@RheumNow #ACR23 Abs#0522 https://t.co/1TBKAxuKPE
Dr. John Cush
Tweet
Good Treatment review of biologics (IL-1, IL-6) in systemic JIA (Stills) including complications of #MAS and lung disease; also info on horizon therapies like JAK inhibitors and IL-18 targeting and novel biomarkers (calgranulins, IL-18 and CXCL9) https://t.co/Cbd7bKdIbb https://t.co/d9tn9fmSAy
Janet Pope
Tweet
Who knew? VEXAS =cluster of findings from a somatic mutation N=110 studying retention of advanced Rx. #JAKi had far better retention than other #Rx. Although there could be channeling bias, I am impressed! Access for off label is a different issue #L03 #ACR23 @RheumNow @ACRheum https://t.co/RE4BVdZeWt
Adela Castro
Tweet
💡RP is a heterogeneous disease.
💡Think VEXAS in RP with MDS.
💡Think MAGIC if oral/genital ulcers.
💡Pts are experts on their own disease! Listen and acknowledge their symptoms. Shout out to Dr @maferradastrong
#ACR23 #ImNotYellingImColombian🇨🇴
@ACRheum @RheumNow https://t.co/nTZ96pJh09
Dr. Antoni Chan
Tweet
Type III relapsing polychondritis has the MAGIC and VEXAS groups, with genital ulcers and haematological manifestations, 8% of RP patients have VEXAS, Ferrada M, #ACR23 @RheumNow https://t.co/FsmBK0F7ZD
Dr. Antoni Chan
Tweet
Things for me to take back to the clinic in looking after JIA patients, Sadun R, #ACR23 @RheumNow https://t.co/YkiP4GZG19
Dr. Antoni Chan
Tweet
New clinical skill to use in the clinic. Auscultate at the TMJ for crepitus and measure the maximal incisal opening in JIA, Sadun R, #ACR23 @RheumNow https://t.co/8koZRCZYoP
Dr. John Cush
Tweet
Anakinra Effective in Systemic JIA, Irrespective of HLA-DRB1 and IL1RN Variants
A prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved to be effective and without potentially allergic lung reactions.
https://t.co/MRFwrCXIlQ https://t.co/Su3nMs4CNW
Dr. John Cush
Tweet
Good Treatment review of biologics (IL-1, IL-6) in systemic JIA (Stills) including complications of #MAS and lung disease; also info on horizon therapies like JAK inhibitors and IL-18 targeting and novel biomarkers (calgranulins, IL-18 and CXCL9) https://t.co/ACe7nDDwop https://t.co/lV66WerkAp
Dr. John Cush
Tweet
Fever of Unknown Origin
Featuring Dr. Sebastian Sattui (Pittsburgh)
68 yr. old with fatigue and daily fevers of 101F; what's the differential diagnosis?
https://t.co/il6EBLOp0M
#PMR https://t.co/PL5DSdRb1s
Dr. John Cush
Tweet
Cardiovascular manifestations of monogenic periodic fever syndromes - includes:
- Pericarditis (most common)
- Cardiac Amyloidosis
- Myocarditis
- CV complications of inflammation and steroid
- Premature atherosclerosis
https://t.co/iLfbPq2nzn https://t.co/T7Vtx5q8Y1
Dr. John Cush
Tweet
Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/vGt12ul6iy https://t.co/044BScmSYc
Dr. John Cush
Tweet
Post hoc analysis 2 phase III RCTs of abatacept (Sc & IV) in 409 polyarticular JIA pcJIA. ABA was effective (by JIA-ACR and JADAS27 responses) & well tolerated, regardless of concomitant or prior MTX use. https://t.co/cTn52V5Fuu https://t.co/CUqin00LZh
Dr. John Cush
Tweet
Multicenter open label trial of 30 refract. Behcets (BD) pts treated w/ tocilizumab (TCZ) x 6 mos; TCZ was effective in 83% (18 complete & 7 partial resp). Complete responses seen w/ uveitis 67%, CNS 60%, mucosal 42%, articular 21%; plus steroid sparing https://t.co/PfrAoQxC2F https://t.co/ocAFv0Y2kr
Dr. John Cush
Tweet
In Memoriam: Dr. K. Frank Austen (1928-2023)
Rheumatology mourns the loss of a historic leader in the field, Dr. K. Frank Austen, who died at his home in Maine on June 23, 2023, at the age of 95.
https://t.co/mtRQ8D5bWt https://t.co/fAQ9ebK95R
